1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Oscotec Inc.

Oscotec Inc.

KKRX:039200
37,250.00
KRW
-250.00
(-0.67%)
1,494.52EPS
34.84P/E
1.94TMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
952.06
735.66
665.28
148.67
153.05
787.78
149.03
1,382.51
122.97
158.11
129.49
892.36
2,609.31
2,654.59
Basic EPS, GAAP
-172.95
-86.95
14.33
-350.68
-229.33
146.2
-765.38
-138.55
-827.49
-763
-635
23
1,368
1,452.35
Free Cash Flow per Basic Share
-132.64
-212.12
-127.59
-346.68
-146.87
-308.71
-158.29
-734.78
-602.01
-864.21
-591.83
-701.28
196.61
775.24
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
943.71
893.6
1,033.44
532.8
744.84
1,566.2
1,664.69
1,706.18
909.93
3,318.41
2,601.57
3,340.22
4,739.05
4,676.3
Tangible Book Value per Share
636.42
581.12
647.62
491.06
709.14
1,528.7
1,617.52
1,666.39
870.49
3,302.35
2,585.9
3,323.79
4,724.53
4,661.91
Basic Weighted Avg Shares
23
23
28
24
26
24
29
31
32
32
38
38
38
38
Sales/Revenue/Turnover
21,859
17,110
18,336
3,554
3,908
18,703
4,369
43,471
3,903
5,062
4,951
34,008
99,839
101,550
Operating Margin (%)
-4.05
-4.42
3.74
-187.26
-148.54
33.03
-454.53
3.64
-719.93
-565.71
-659.58
-8.04
52.17
49.64
Depreciation Expense
410
412
514
391
317
308
621
1,069
1,544
1,766
1,857
1,939
1,648
1,513
Net Income, GAAP
-3,971
-2,022
395
-8,383
-5,857
3,471
-22,436
-4,357
-26,263
-24,430
-24,280
877
52,343
55,559
Effective Tax Rate (%)
- -
- -
- -
- -
- -
17.71
- -
258.26
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-18.17
-11.82
2.15
-235.87
-149.84
18.56
-513.57
-10.02
-672.93
-482.57
-490.4
2.58
52.43
54.71
Working Capital
8,395
7,883
8,772
8,629
17,820
41,595
40,855
39,422
2,548
89,297
67,580
106,440
159,982
155,314
LT Debt
1,620
1,786
- -
2,180
2,081
1,685
1,322
1,311
775
319
82
73
49
190
Total Equity
22,165
21,783
26,918
16,553
25,653
51,669
54,366
57,241
31,189
121,821
94,717
132,360
186,848
182,532
Return on Invested Capital (%)
- -
- -
- -
- -
- -
9.97
- -
-4.15
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
7.29
- -
-12.98
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-17.39
-9.5
1.67
-41.39
-32.96
10.31
-46.29
-8.42
-64.53
-32.42
-22
0.77
33.87
36.95

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
14,822
15,569
16,741
LT Borrowings
- -
- -
- -
LT Finance Leases
67
49
190
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
38
38
38
Market Capitalization
1,792,255
1,729,270
1,935,864

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
125,412
198,958
190,865
Cash, Cash Equivalents & STI
108,949
108,087
158,503
Accounts Receivable, Net
13,732
87,634
28,870
Inventories
1,754
1,815
1,632
Total Current Liabilities
28,837
38,976
35,551
Payables & Accruals
- -
- -
- -
ST Debt
14,822
15,569
16,741
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
43.22%
60.75%
41.17%
Free Cash Flow
43.68%
-20.15%
-128.15%
Net Income, GAAP
302.49%
1,252.66%
5,871.65%
Sales/Revenue/Turnover
184.33%
143.39%
193.58%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,062
1,554
29,056
2,336
34,008
2025
1,936
10,017
8,945
78,940
99,839
2026
3,648
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-142
-149
442
-127.12
23
2025
-155
-48.28
-12.79
1,584.5
1,368
2026
-71.23
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tae-Young Yun
Full Time Employees
57
Sector
Health technology
Industry
Pharmaceuticals: major
Address
A Building, Korea Bio Park Seongnam-si GY South Korea 13488
IPO Date
Jan 17, 2007
Website
oscotec.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Oscotec Inc. (KOSDAQ: 039200) operates as a biotechnology company focused on drug development, functional materials, dental bone graft materials, and related healthcare products; it develops pipeline candidates including SKI-O-703, a SYK inhibitor in Phase 2 clinical trials for rheumatoid arthritis and idiopathic thrombocytopenic purpura, SKI-G-801, a selective FLT3/AXL inhibitor in Phase 1 for acute myeloid leukemia and solid tumors, lazertinib, a third-generation EGFR inhibitor in Phase 3 for non-small cell lung cancer, and an Anti-Tau antibody in Phase 1a/1b for Alzheimer's disease; the company offers dental health products such as bone grafts InduCera, BioCera-F, and SynCeraII, membranes LysoGide and CollaGuide, and functional ingredients including OPB for osteoporosis, AIF for arthritis, SGA for bone growth enhancement, and PRF-K for periodontal diseases. Founded in 1998 and headquartered in Seongnam, South Korea, Oscotec primarily serves pharmaceutical, dental, and functional health markets with operations centered in South Korea and global clinical trial partnerships. Recent developments include its SYK inhibitor program receiving funding from the Korea Drug Fund, subsidiary Genosco submitting an IND application to the U.S. FDA for ROCK2 inhibitor GNS-3545 in Phase 1 for idiopathic pulmonary fibrosis in August 2025, and prior oncology collaborations such as the terminated partnership with Beactica Therapeutics on LSD1-targeted degraders and benefits from Johnson & Johnson's positive NSCLC trial data involving lazertinib in January 2025.